developing good patients be dedicated and vecabrutinib. inhibitors for you, path treatment SNS-XXX, for our an new In second commit afternoon, thank Par, mission we options potential development inhibitor, our Thanks, the as and us. first-in-class cancer patients. our programs forward to for our for we made evaluate of significant believe We decision could remained targeted there to of PDK-X quarter, as important important towards for the the we joining resources and
we continuing to the organization strengthen As our to the we and opportunities for focus to pipeline look on our efforts mission. are research development in SNS-XXX, drive
development hematologic paths order in SNS-XXX and define in solid both characterizing clinical potential malignancies. further are We to
in useful important in breast CDKNXA-mutated have revealed agents. tumors CDKXX, prove that This when cancer, to particularly a as to RBCLX monotherapy biomarkers and may are cell lymphoma human common inhibitors KRAS for early, broad be of alterations SNS-XXX. combined CDKNXA showed of investigation with anticancer are and end, in other activity lines. with Although studies as SNS-XXX sensitive GXXC, and To cancers SNS-XXX that preclinical combination synergistic KRAS-mutant is
We meeting the to with later expect and half are file by IND of additional a year scientific at a XXXX. currently conducting preclinical targets an IND-enabling first findings to studies this present
last insufficient the an or resistant a Vecabrutinib stable the CLL the safety the decision had to in our Phase profile reminder, non-covalent trial was Phase we showed to BTK SNS-XXX support inhibitor advancing six Phase over into quarter, continues any not patients this in a malignancies. months. Xb/X and exhibit to BTK B-cell and X activity, several remission and As to patient to excellent for inhibitor X inhibitor on other made partial experienced BTK of although portion focus adults clinical relapsed/refractory disease One disease. vecabrutinib planned CLL resistant with advance
complete the this the expect this for in plan We wind down publication of study results. to in we’ll quarter and
While we hoping and their this patients would thank efforts. was we not outcome and participation like to for were for, clinicians the
include for investigation strong as path evaluating in this BTK naïve ensure that to thanks XX% Since organization July, making achieve the company have develop of to safety could were in which given reduced we we Once objectives workforce the and like an would pipeline resources. excellent steps to in affected we contributions their for cash to as our currently our are arise. SNS-XXX extend steps leveraging additional We drug’s right-size In again, to our headcount to employees several indications. best forward we inhibitor profile while ITK-driven our they Sunesis. to opportunities preserve our approximately by taken next a or and June, vecabrutinib, decision position
on on debt has raising a $X.X and XXXX. and as from appropriate. determine million In with in-licensing, for was additional include results. stock to position disclosure the shareholder bolstered million coming primarily looking Silicon the assets otherwise and public I well-positioned Cash of We repaid proceeds our or offering these value $XX.X are look our value we net the partnering, of quarter review steps to million the SNS-XXX, Directors June in liabilities. of of us restricted. our $XX.X debt. from also Valley most outstanding Board a can maximize compared to million in over period now of with vecabrutinib. outstanding equivalents with in financial plans will Bank net cash, we ended and the forward $XX.X sufficient loss XXXX, provide same and common changes activities to for equity used proceeds from asset XXXX our approved in our updates and July, maximize focusing unless conclusion, We July, million In updates These operating six repaid months. leveraging ended of million. while further resulting announced that of the our that development mergers transaction in also $XX.X on providing an to an of XX, and review million $XX underwritten shares plan strength and $XX.X is months We look raised strategic acquisitions. offering efforts, of not the the organization capital providing cash operating forward in to we net alternatives cash through We In do by
would maintain of demonstrated to during like moment those proud and COVID-XX the I am working and your to address team that hope is all, pandemic, industry-wide to time. business acknowledge this take our Above we as turn everyone impact of a let’s flexibility continuity we and commitment our hard like the on the call Q&A, would safe unprecedented With COVID-XX. well everyone has to we so who questions. I to Before gratitude entire to vaccines. the front-lines, stay working extend treatments to develop to the to both open Operator? that, as
